Latest Manufacturing News

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.

Pure Resources has deepened its partnership with Rice University to develop carbon nanotube fibre thermal management technology aimed at AI and defence markets, leveraging its Garnet Hills graphite for a vertically integrated IP pipeline.

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.

Lynas Rare Earths reported a record A$265 million quarterly revenue in Q3 FY26, driven by higher NdPr prices and production milestones including early Samarium oxide output. The company secured a 10-year Malaysian operating licence and extended a key supply deal with Japanese partner JARE through 2038.

Bioxyne Limited posted a record $21.3 million revenue in Q3 FY26, driven by strong demand for medicinal cannabis and psychedelics. The company secured a manufacturing agreement with Aurora Cannabis and initial orders for GMP psilocybin capsules, reaffirming FY26 guidance.

OD6 Metals has secured a strategic foothold in the US critical minerals market by acquiring the Quinn Fluorspar Project in Nevada, delivering ultra-high-grade assay results and commencing systematic exploration. Meanwhile, metallurgical progress at its Splinter Rock rare earths project and new copper targets at Gulf Creek underpin a diversified critical minerals portfolio.

AnteoTech (ASX: ADO) pushed forward its advanced battery and life sciences technologies in the March 2026 quarter, achieving key product validations and expanding its sales pipeline to record levels. The company ended the period with A$3.3 million cash and no debt following a recent A$3.5 million capital raise.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

MyEco Group has locked in $0.92 million through its Series 2 convertible note program, reinforcing its growth trajectory with funding earmarked for a new GRS-certified recycled bin liner range. The raise supplements a solid cash position while aiming to limit shareholder dilution amid challenging market conditions.

Patrys has raised A$3.2 million through a share placement to fund its injectable quetiapine program’s Phase 1A clinical trial and FDA pre-IND preparations.

Green360 Technologies has produced its first commercial batch of Eco-Clay under a tolling deal with Calix, advancing its low-carbon cement alternative towards market entry in Victoria by mid-2026.

DXN Limited has secured a A$5.3 million contract to deliver a modular Cable Landing Station in South America, marking its first foray into the Latin American market and reinforcing its role in hyperscale internet infrastructure.